Q3FY18 Results: Fairchem Speciality reports PAT surges of 39 per cent
Q3FY18 Results: Fairchem Speciality reports PAT surges of 39 per cent

Q3FY18 Results: Fairchem Speciality reports PAT surges of 39 per cent

Nidhi Jani Article rating: 4.5

EBITDA for the quarter rose by 35.6 per cent yoy to Rs. 28.51 crore with a corresponding margin contraction of 110 bps. EBITDA margin for the quarter stood at 10.5 per cent. This margin contraction was led by jump in power and fuel expenses and cost of materials by 46.3 per cent yoy and 13.7 per cent yoy, respectively.

Paper stocks face dilemma of rise in pulp prices
Paper stocks face dilemma of rise in pulp prices

Paper stocks face dilemma of rise in pulp prices

Bhagyashree Vivarekar Article rating: 3.3

In the near future, Indian paper manufacturers are expected to feel the blow of the hiked imported pulp prices. Of-late, imported pulp prices have peaked to 7 year highs and are expected to remain higher for some period. 

Vakrangee hits upper circuit on capital allocation policy
Vakrangee hits upper circuit on capital allocation policy

Vakrangee hits upper circuit on capital allocation policy

Nikita Singh Article rating: 4.4

IT company Vakrangee hit its upper circuit on the bourses on Monday for the second consecutive trade session as the company announced its capital allocation policy, also announcing that it is a debt free company. 

Bank Nifty surges nearly 1 per cent; still indecisive
Bank Nifty surges nearly 1 per cent; still indecisive

Bank Nifty surges nearly 1 per cent; still indecisive

Amir Shaikh Article rating: 5.0

Bank Nifty index surged nearly 0.9 per cent, outpacing the benchmark indices, though marginally. The level of 25370 followed by 25150-25025 will act as major supports for the index.

Lupin launches generic version of Tamiflu in US
Lupin launches generic version of Tamiflu in US

Lupin launches generic version of Tamiflu in US

Gayathri Udyawar Article rating: 5.0

Generics pharma giant Lupin announced the launch of Oseltamivir Phosphate Capsules in the US market. The drugmaker had earlier received USFDA approval for the same.

Q3FY18 Results: Lumax Auto Tech reports PAT jump of 2.5 times
Q3FY18 Results: Lumax Auto Tech reports PAT jump of 2.5 times

Q3FY18 Results: Lumax Auto Tech reports PAT jump of 2.5 times

Nidhi Jani Article rating: 5.0

The PAT for the quarter came in at Rs. 14.89 crore, yoy increase of 160.8 per cent. This was due to sharp jump in other income from Rs. 0.79 crore to Rs. 2.7 crore. Also, decline in interest expenses by 35 per cent yoy aided to bottomline growth.

Q3FY18 Results: PAT of Kwality melts by 53.6 per cent
Q3FY18 Results: PAT of Kwality melts by 53.6 per cent

Q3FY18 Results: PAT of Kwality melts by 53.6 per cent

Amir Shaikh Article rating: 5.0

The PAT for the quarter came in at Rs. 20.93 crore, yoy decline of 53.6 per cent. This was due to sharp decline in other income to Rs. 0.22 crore as against Rs. 5.03 crore in corresponding quarter of last year. 

RSS
First34323433343434353437343934403441Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR